238 related articles for article (PubMed ID: 32563721)
1. Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study.
Yamamoto-Furusho JK; Al Harbi O; Armuzzi A; Chan W; Ponce de Leon E; Qian J; Shapina M; Toruner M; Tu CH; Ye BD; Guennec M; Sison C; Demuth D; Fadeeva O; Khan QMR
Dig Liver Dis; 2020 Aug; 52(8):869-877. PubMed ID: 32563721
[TBL] [Abstract][Full Text] [Related]
2. Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study.
Balderramo D; Yamamoto-Furusho J; Ponce de León E; de María J; Zubiaurre I; Pedreira S; Lis C; Brion L; de Paula JA
Gastroenterol Hepatol; 2024 Jan; 47(1):51-62. PubMed ID: 37062500
[TBL] [Abstract][Full Text] [Related]
3. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study.
Li J; Liu Z; Hu P; Wen Z; Cao Q; Zou X; Chen Y; Wang Y; Zhong J; Shen X; Demuth D; Fadeeva O; Xie L; Chen J; Qian J
BMC Gastroenterol; 2022 Feb; 22(1):44. PubMed ID: 35120446
[TBL] [Abstract][Full Text] [Related]
4. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
[TBL] [Abstract][Full Text] [Related]
5. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease.
Bank S; Julsgaard M; Abed OK; Burisch J; Broder Brodersen J; Pedersen NK; Gouliaev A; Ajan R; Nytoft Rasmussen D; Honore Grauslund C; Roug S; Galsgaard J; Sprogøe Høyer Finsen D; Lindby K; ; Sørensen J; Larsen L; Rohr Andersen M; Brandslund I; Thomassen M; Green A; Bo Bojesen A; Bek Sørensen S; Vogel U; Andersen V
Aliment Pharmacol Ther; 2019 Apr; 49(7):890-903. PubMed ID: 30811631
[TBL] [Abstract][Full Text] [Related]
7. High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists.
Guo A; Ross C; Chande N; Gregor J; Ponich T; Khanna R; Sey M; Beaton M; Yan B; Kim RB; Wilson A
Sci Rep; 2022 Jan; 12(1):1185. PubMed ID: 35075155
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
Goll R; Moe ØK; Johnsen KM; Meyer R; Friestad J; Gundersen MD; Kileng H; Johnsen K; Florholmen JR
BMC Gastroenterol; 2022 Nov; 22(1):464. PubMed ID: 36384462
[TBL] [Abstract][Full Text] [Related]
9. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.
Murthy SK; Begum J; Benchimol EI; Bernstein CN; Kaplan GG; McCurdy JD; Singh H; Targownik L; Taljaard M
Gut; 2020 Feb; 69(2):274-282. PubMed ID: 31196874
[TBL] [Abstract][Full Text] [Related]
10. Impact of antitumour necrosis factor therapy on surgery in inflammatory bowel disease: a population-based study.
Hawthorne AB; Arms-Williams B; Cannings-John R; Pollok RCG; Berry A; Harborne P; Trivedi A
BMJ Open Gastroenterol; 2024 May; 11(1):. PubMed ID: 38777566
[TBL] [Abstract][Full Text] [Related]
11. Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study.
Shin JY; Park HM; Lee MY; Jeon JY; Yoo HJ; Ye BD
Gut Liver; 2021 Nov; 15(6):867-877. PubMed ID: 33785664
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
Kirchgesner J; Lemaitre M; Rudnichi A; Racine A; Zureik M; Carbonnel F; Dray-Spira R
Aliment Pharmacol Ther; 2017 Jan; 45(1):37-49. PubMed ID: 27781286
[TBL] [Abstract][Full Text] [Related]
13. The incidence, clinical characteristics and serological characteristics of anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: A systematic review and meta-analysis.
Dai C; Wang YN; Tian WN; Huang YH; Jiang M
Int Immunopharmacol; 2022 Nov; 112():109269. PubMed ID: 36182873
[TBL] [Abstract][Full Text] [Related]
14. BIOLOGICAL THERAPY PENETRATION FOR INFLAMMATORY BOWEL DISEASE IN LATIN AMERICA: CURRENT STATUS AND FUTURE CHALLENGES.
Quaresma AB; Coy CSR; Damião AOMC; Kaplan GG; Kotze PG
Arq Gastroenterol; 2019; 56(3):318-322. PubMed ID: 31633732
[TBL] [Abstract][Full Text] [Related]
15. Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review.
Kotze PG; Underwood FE; Damião AOMC; Ferraz JGP; Saad-Hossne R; Toro M; Iade B; Bosques-Padilla F; Teixeira FV; Juliao-Banos F; Simian D; Ghosh S; Panaccione R; Ng SC; Kaplan GG
Clin Gastroenterol Hepatol; 2020 Feb; 18(2):304-312. PubMed ID: 31252191
[TBL] [Abstract][Full Text] [Related]
16. Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis.
Targownik LE; Tennakoon A; Leung S; Lix LM; Singh H; Bernstein CN
Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1061-1070.e1. PubMed ID: 28238957
[TBL] [Abstract][Full Text] [Related]
17. A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia.
Mokhtar NM; Nawawi KNM; Verasingam J; Zhiqin W; Sagap I; Azman ZAM; Mazlan L; Hamid HA; Yaacob NY; Rose IM; Den ELN; Wan MS; Raja Ali RA
BMC Public Health; 2019 Jun; 19(Suppl 4):550. PubMed ID: 31196184
[TBL] [Abstract][Full Text] [Related]
18. Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia.
Ng SC; Zeng Z; Niewiadomski O; Tang W; Bell S; Kamm MA; Hu P; de Silva HJ; Niriella MA; Udara WS; Ong D; Ling KL; Ooi CJ; Hilmi I; Lee Goh K; Ouyang Q; Wang YF; Wu K; Wang X; Pisespongsa P; Manatsathit S; Aniwan S; Limsrivilai J; Gunawan J; Simadibrata M; Abdullah M; Tsang SW; Lo FH; Hui AJ; Chow CM; Yu HH; Li MF; Ng KK; Ching JY; Chan V; Wu JC; Chan FK; Chen M; Sung JJ;
Gastroenterology; 2016 Jan; 150(1):86-95.e3; quiz e13-4. PubMed ID: 26385074
[TBL] [Abstract][Full Text] [Related]
19. Trends of Utilization of Tumor Necrosis Factor Antagonists in Children With Inflammatory Bowel Disease: A Canadian Population-Based Study.
El-Matary W; Leung S; Tennakoon A; Benchimol EI; Bernstein CN; Targownik LE
Inflamm Bowel Dis; 2020 Jan; 26(1):134-138. PubMed ID: 31323083
[TBL] [Abstract][Full Text] [Related]
20. Dose Augmentation of Tumor Necrosis Factor Inhibitors is Frequently Performed in Persons With Inflammatory Bowel Disease in the Absence of Objective Evidence of Active Inflammation.
Elias ED; Bernstein CN; Singh H; Oketola A; Krishnan S; Targownik LE
J Clin Gastroenterol; 2021 Aug; 55(7):602-608. PubMed ID: 32694264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
